These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30352456)

  • 21. Copeptin and mid-regional pro-atrial natriuretic peptide in women with suspected or confirmed pre-eclampsia: comparison with sFlt-1/PlGF ratio.
    Neuman RI; van der Meer MMA; Saleh L; van den Berg SAA; van den Meiracker AH; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2020 Dec; 56(6):872-878. PubMed ID: 31975510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Heinonen S; Hämäläinen E; Pulkki K; Romppanen J; Laivuori H;
    Pregnancy Hypertens; 2018 Oct; 14():252-259. PubMed ID: 29803331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating endocan and preeclampsia: a meta-analysis.
    Lan X; Liu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31854443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
    Moe K; Heidecke H; Dechend R; Staff AC
    Pregnancy Hypertens; 2017 Oct; 10():83-89. PubMed ID: 29153696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia.
    Garg P; Jaryal AK; Kachhawa G; Deepak KK; Kriplani A
    Pregnancy Hypertens; 2018 Oct; 14():245-251. PubMed ID: 29548740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum endocan concentration in women with pre-eclampsia.
    Yuksel MA; Tuten A; Oncul M; Acikgoz AS; Temel Yuksel I; Toprak MS; Ekmekci H; Balci Ekmekci O; Madazli R
    Arch Gynecol Obstet; 2015 Jul; 292(1):69-73. PubMed ID: 25534164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolomic biomarkers in midtrimester maternal plasma can accurately predict the development of preeclampsia.
    Lee SM; Kang Y; Lee EM; Jung YM; Hong S; Park SJ; Park CW; Norwitz ER; Lee DY; Park JS
    Sci Rep; 2020 Sep; 10(1):16142. PubMed ID: 32999354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis biomarkers for the prediction of severe adverse outcomes in late-preterm preeclampsia.
    Villalain C; Herraiz I; Cantero B; Quezada S; Lopez A; Simón E; Galindo A
    Pregnancy Hypertens; 2020 Jan; 19():74-80. PubMed ID: 31927324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
    Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy.
    Szpera-Goździewicz A; Kosicka K; Goździewicz T; Krzyścin M; Wirstlein P; Siemiątkowska A; Główka FK; Wender-Ożegowska E; Markwitz W; Bręborowicz GH
    J Matern Fetal Neonatal Med; 2020 Jul; 33(14):2313-2319. PubMed ID: 30501553
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
    Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.